Century Therapeutics, Inc. (NASDAQ:IPSC) Stock Has Consensus Target Price of $4.75

Key Points

• Century Therapeutics has a consensus “Hold” rating from seven analysts, with four buys, two holds and one sell. The average 12-month price target is $4.75.
• Institutional investors and hedge funds own 50.20% of the company, with several firms initiating positions during the second quarter, including Seven Fleet Capital Management’s $10.65 million stake.
• The stock opened at $1.44 and has a market capitalization of approximately $260.7 million. Century reported a quarterly loss of $0.17 per share, missing the $0.11 consensus estimate.

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has been assigned an average rating of "Hold" from the seven research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $4.75.

Several equities research analysts have commented on IPSC shares. Wall Street Zen upgraded shares of Century Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, September 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Century Therapeutics in a research report on Tuesday, September 29th.

Institutional Trading of Century Therapeutics

Large investors have recently added to or reduced their stakes in the business. Spark Investment Management LLC bought a new stake in Century Therapeutics during the 2nd quarter valued at $145,000. AXQ Capital LP bought a new position in shares of Century Therapeutics in the second quarter worth $145,000. Wellington Management Group LLP bought a new position in shares of Century Therapeutics in the second quarter worth $201,000. Seven Fleet Capital Management LP acquired a new position in shares of Century Therapeutics during the second quarter valued at $10,652,174. Finally, Bank of America Corp DE acquired a new position in shares of Century Therapeutics during the second quarter valued at $389,000. 50.20% of the stock is currently owned by institutional investors and hedge funds.

Century Therapeutics Stock Performance

Century Therapeutics stock opened at $1.44 on Tuesday. Century Therapeutics has a one year low of $0.43 and a one year high of $3.04. The company has a 50-day simple moving average of $1.88 and a 200-day simple moving average of $2.12. The firm has a market capitalization of $260.74 million, a P/E ratio of -1.55 and a beta of 1.67.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.06). As a group, sell-side analysts forecast that Century Therapeutics will post -0.51 earnings per share for the current year.

Century Therapeutics Company Profile

Century Therapeutics, Inc NASDAQ: IPSC is a biotechnology company developing allogeneic cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create potentially scalable immune-cell products designed to treat patients without relying on cells collected from each individual patient.

Century's research focuses primarily on iPSC-derived natural killer (NK) cells and T cells that are genetically engineered to recognize and attack cancer cells. Its pipeline has included investigational chimeric antigen receptor (CAR) cell therapies targeting blood cancers, including B-cell malignancies, with the goal of providing readily available, “off-the-shelf” treatments.

Founded in 2018 and headquartered in Philadelphia, Pennsylvania, Century Therapeutics conducts research and development activities in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.